FEATURES OF THE MANAGEMENT OF A COMORBID PATIENT WITH METABOLIC SYNDROME AND CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

Authors:

Abstract:

Angiotensin-converting enzyme inhibitors or the combination of sacubitril and valsartan, beta-blockers, mineralocorticoid receptor antagonists, and sodium-dependent inhibitors of glucose-like cotransporter type 2 (SGLT2) are the standard of care for chronic heart failure with reduced ejection fraction (HFrEF). The implementation of an SGLT2 (Empagliflozin) in heart failure phenotype with reduced ejection fraction with/without type 2 diabetes and eGFR ≥ 20 mL/min/1.73 m2 is the result of the randomized, double-blind, placebo-controlled clinical trial EMPEROR-Reduced. Empagliflozin reduces the combined risk of death and hospitalization by 25 % and 30 % respectively, and slows the development of chronic renal failure in individuals with heart failure with reduced ejection fraction with/without type 2 diabetes. The presented clinical case corresponds to the results of the EMPEROR- Reduced clinical trial and shows that empagliflozin 10 mg/day in comorbid patients with the heart failure phenotype with reduced ejection fraction contributes not only to the improvement of left ventricular systolic function and quality of life, increased exercise tolerance and reduced frequency of hospitalizations, but also to the reduction of glycemia, normalization of blood lipid spectrum and indicators of nitrogen excretory renal function.

Keywords:

heart failure coronary heart disease myocardial infarction cardiomyopathy sodium-dependent inhibitors of glucose-like cotransporter type 2 metabolic syndrome

References:

1. AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Heidenreich PA, Bozkurt CB, Aguilar D, Allen LA, Byun JJ , Colvin MM , et al. Circulation. Volume 145, Number 18 . doi : 10.1161/CIR.0000000000001062.
2. Abdi A, Al Otaiby S, Badarin FA, Khraibi A, Nader M. Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy. Biomedicine and Pharmacotherapy. 2022; 146: 112518. doi: 10.1016/j.biopha.2021.112518.
3. Alnima T, Mulder MMG, van Bussel BCT, Ten Cate H. COVID-19 coagulopathy: from pathogenesis this treatment. Acta Haematologica. 2022; 145:282-296. doi: 10.1159/000522498.
4. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and Health-Related Quality of Life Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: The EMPEROR – Reduced trial. European Heart Journal. 2021; 42:1203-12 . doi : 10.1093/ eurheartj /ehaa1007.
5. Chen MB, Wang H, Cui WY, Xu HL, Zheng QH. Effect of SGLT inhibitors on weight and lipid metabolism at 24 weeks of treatment in patients with diabetes mellitus: A systematic review and network meta-analysis . Medicine (Baltimore). 2021 Feb 12; 100(6): e24593. doi: 10.1097/MD.0000000000024593.
6. Delorey TM, Ziegler CG, Heimberg G, Normand R, Yang Y, Segerstolpe Å, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 2021; 595: 107–113. doi: 10.1038/s41586-021-03570-8.
7. Imig JD. SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clinical Science. 2022; 136: 431–434. doi: 10.1042/CS20220028.
8. Lasica R, Djukanovic L, Mrdovic I, Savic L, Ristic A, Zdravkovic M, et al. Acute Coronary Syndrome in the COVID-19 Era — Differences and Dilemmas Compared this the Pre-COVID-19 Era. Clinical Medicine. 2022; 11: 3024. doi: 10.3390/jcm11113024.
9. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart. European Heart Journal . 2023; 44:3627-3639. doi: 10.1093/ eurheartj /ehad195.
10. Nazarova MS, Stanislavchuk MA, Burdeina LV, Bunny NV. Antiphospholipid and antineutrophil antibodies levels in men with stable coronary heart disease and postinfarction cardiosclerosis and its relationship with the disease manifestation Message Medical. 2020; 73(3):466 – 470. doi: 10.36740/WLek202003111.
11. Nicin L, Abplanalp WT, Mellentin H, Kattih B, Tombor L, John D, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. European Heart Journal. 2020; 41: 1804–1806. doi: 10.1093/ eurheartj /ehaa311.
12. Packer M, Butler J, Zeller C. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. Circulation. 2023; 148:1011-22. doi: 10.1161/CIRCULATIONAHA.123.06574.
13. Rus M, Ardelean AI, Andronie-Cioara FL, Filimon GC. Acute Myocardial Infarction during the COVID-19 Pandemic: Long-Term Outcomes and Prognosis -A Systematic Review. Life 2024; 14 (2):202. doi: 0.3390/life14020202.
14. Zhang L, Richards A, Barrasa MI, Hughes SH, Young RA, Jaenisch R. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proceedings of the National Academy of Science of the United States of America. 2021; 118: e2105968118. doi: 10.1073/pnas.2105968118.
15. Zuin M, Rigatelli G, Battisti V, Costola G, Roncon L, Bilato C. Increased risk of acute myocardial infarction after COVID-19 recovery: A systematic review and meta-analysis. International Journal of Cardiology. 2022 Dec 16; 372:138–143. doi: 10.1016/j.ijcard.2022.12.032.

Publication:

«World of Medicine and Biology» Vol. 21 No. 93 (2025) , с. 261-266
УДК 616.12-008.331.1-08:616.152.1:616.12-008.46

DOI:

https://doi.org/10.26724/2079-8334-2025-3-93-261-266